drugset

drugset / Trial / NCT01872078

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

NCT01872078 ↗

Phase 2 Completed 67 enrolled AstraZeneca

RandomizedParallel-groupDouble-blindBasic science

Summary

To assess the effects of AZD4901 when given in multiple doses to females with Polycystic Ovary Syndrome

Timeline

Start: 2013-06
Primary completion: 2014-07
Completion: 2014-07

Publications

George JT, Kakkar R, Marshall J, Scott ML, Finkelman RD, Ho TW, Veldhuis J, Skorupskaite K, Anderson RA, McIntosh S, Webber L. Neurokinin B Receptor Antagonism in Women With Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial. J Clin Endocrinol Metab. 2016 Nov;101(11):4313-4321. doi: 10.1210/jc.2016-1202. Epub 2016 Jul 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PAVINETANT	Small molecule	20 mg	Oral
Subject	PAVINETANT	Small molecule	40 mg	Oral
Subject	PAVINETANT	Small molecule	80 mg	Oral

Indications